JP2022530037A5 - - Google Patents

Info

Publication number
JP2022530037A5
JP2022530037A5 JP2021562962A JP2021562962A JP2022530037A5 JP 2022530037 A5 JP2022530037 A5 JP 2022530037A5 JP 2021562962 A JP2021562962 A JP 2021562962A JP 2021562962 A JP2021562962 A JP 2021562962A JP 2022530037 A5 JP2022530037 A5 JP 2022530037A5
Authority
JP
Japan
Prior art keywords
item
tcr
nucleic acid
acid molecule
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029344 external-priority patent/WO2020219563A1/en
Publication of JP2022530037A publication Critical patent/JP2022530037A/ja
Publication of JP2022530037A5 publication Critical patent/JP2022530037A5/ja
Pending legal-status Critical Current

Links

JP2021562962A 2019-04-22 2020-04-22 融合タンパク質を使用するtcr再プログラミングのための組成物及び方法 Pending JP2022530037A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962836977P 2019-04-22 2019-04-22
US62/836,977 2019-04-22
US201962943679P 2019-12-04 2019-12-04
US62/943,679 2019-12-04
PCT/US2020/029344 WO2020219563A1 (en) 2019-04-22 2020-04-22 Compositions and methods for tcr reprogramming using fusion proteins

Publications (2)

Publication Number Publication Date
JP2022530037A JP2022530037A (ja) 2022-06-27
JP2022530037A5 true JP2022530037A5 (cg-RX-API-DMAC7.html) 2023-04-28

Family

ID=72941760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562962A Pending JP2022530037A (ja) 2019-04-22 2020-04-22 融合タンパク質を使用するtcr再プログラミングのための組成物及び方法

Country Status (7)

Country Link
US (1) US20220362295A1 (cg-RX-API-DMAC7.html)
EP (1) EP3959322A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022530037A (cg-RX-API-DMAC7.html)
CN (1) CN114258430A (cg-RX-API-DMAC7.html)
AU (1) AU2020262111A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137519A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020219563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
US20220288176A1 (en) * 2019-08-28 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University Circular rna modification and methods of use
KR20230028375A (ko) 2020-06-25 2023-02-28 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 원형 rna 번역을 구동하는 유전 요소와 이를 사용하는 방법
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
EP3964585A1 (en) * 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
JP2023543361A (ja) * 2020-09-29 2023-10-13 ニューエクセル・セラピューティクス・インコーポレイテッド Neurod1及びdlx2ベクター
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
CN114516913B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测试剂盒
CN112481289B (zh) * 2020-12-04 2023-06-27 苏州科锐迈德生物医药科技有限公司 一种转录环状rna的重组核酸分子及其在蛋白表达中的应用
CN114630909B (zh) * 2020-12-04 2024-05-28 苏州科锐迈德生物医药科技有限公司 环状rna、包含环状rna的疫苗及用于检测新型冠状病毒中和抗体的试剂盒
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
WO2023070043A1 (en) * 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
WO2023133358A2 (en) * 2022-01-10 2023-07-13 2Seventy Bio, Inc. Muc16 chimeric antigen receptors
CN114606263B (zh) * 2022-05-11 2022-09-06 上海优替济生生物医药有限公司 分离的核酸分子及其用途
EP4569121A4 (en) * 2022-09-10 2025-12-24 Exclcirc Suzhou Biomedical Co Ltd CIRCULAR RNA AND ASSOCIATED PREPARATION PROCESSES
CN116411023B (zh) * 2023-02-24 2025-08-12 北京大学人民医院 一种新型环状rna成环序列构建car-t细胞及在治疗小细胞肺癌中的应用
WO2024215872A1 (en) * 2023-04-11 2024-10-17 The Regents Of The University Of California Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma
WO2024236366A2 (en) * 2023-05-12 2024-11-21 Sekkei Bio Private Limited Design and method of generating scarless circular rna
CN121450713A (zh) * 2024-07-31 2026-02-03 上海生物制品研究所有限责任公司 一种用于制备环状rna的载体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034925A1 (en) * 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102427334B1 (ko) * 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
BR112019007100A2 (pt) * 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
WO2018232020A1 (en) * 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2019222275A2 (en) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins

Similar Documents

Publication Publication Date Title
US12091459B2 (en) Bispecific chimeric antigen receptors, encoding polynucleotides and use of receptors thereof to treat cancer
JP7320560B2 (ja) 治療免疫細胞の有効性を改良するための方法
TWI905076B (zh) 非複製勝任型重組反轉錄病毒顆粒及其用途
EP4303233A1 (en) Targeted protein degradation system and use thereof
US20230295296A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP6775515B2 (ja) トランスポザーゼポリペプチド及びその使用
CA3139032A1 (en) Circular rna compositions and methods
CN114258430A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
AU2018202294A1 (en) Trifunctional T cell-antigen coupler and methods and uses thereof
JP2021515598A5 (cg-RX-API-DMAC7.html)
CN107002084A (zh) 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
JP2016539929A (ja) 免疫療法のためのポリクローナルγδT細胞
JP2025010249A (ja) 二量体形成剤調節性免疫受容体複合体
JP2024036482A (ja) Daricインターロイキン受容体
JP7778130B2 (ja) 組換えerIL-15 NK細胞
CN110914431A (zh) 经人工操纵的免疫细胞
US20230348556A1 (en) Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
CN113891718A (zh) 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
CN114514247A (zh) Car-cd123载体及其用途
US12606603B2 (en) IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy
KR20260069537A (ko) 바이러스 벡터 및 생산자 세포
US20250340599A1 (en) Targeted protein degradation system and use thereof
HK40117709A (en) Methods for engineering and use of scarless ring mrna to engineer cells and their uses
HK40086170A (en) Methods for enhancing efficacy of therapeutic immune cells
KR20240094169A (ko) B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도